Patents Assigned to argenx IIP BV
  • Therapeutic musk antibodies
    Patent number: 11492401
    Abstract: The present invention relates to antibody-based molecules, including full-length antibodies, antigen-binding domains thereof, and antibody derivatives that are capable of binding to and activating human muscle-specific tyrosine protein kinase (MuSK). The present invention further discloses methods of treating neuromuscular conditions using the aforementioned MuSK antibodies.
    Type: Grant
    Filed: December 30, 2021
    Date of Patent: November 8, 2022
    Assignees: NEW YORK UNIVERSITY, ARGENX IIP BV
    Inventors: Steven J. Burden, Shohei Koide, Akiko Koide, Nadia Leloup, Julien Oury, Karen Silence, Roeland Vanhauwaert, Christophe Blanchetot
  • Galectin-10 antibodies
    Patent number: 11066473
    Abstract: The present invention relates to antagonists, particularly antibodies and antigen binding fragments thereof, that bind to the protein galectin-10, particularly human galectin-10. The galectin-10 antagonists disrupt the crystallization of galectin-10 and are therefore useful in methods of preventing and treating diseases and conditions wherein the pathology is linked to the formation/presence of Charcot-Leyden crystals (CLCs).
    Type: Grant
    Filed: April 12, 2019
    Date of Patent: July 20, 2021
    Assignees: argenx IIP BV, VIB VZW, Universiteit Gent
    Inventors: Jean-Michel Percier, Christophe Blanchetot, Michael Saunders, Hans De Haard, Sebastian Van Der Woning, Emma Persson, Bart Lambrecht, Savvas Savvides, Hamida Hammad, Kenneth Verstraete